Several single-tablet regimens (STRs) are now available and are recommended for first-line antiretroviral therapy (ART); however, STR use for youth with HIV (YHIV) has not been systematically studied. We examined the characteristics associated with initiation of STRs versus multi-tablet regimens (MTRs) and the virological outcomes for youth with nonperinatally acquired HIV (nPHIV).
Introduction
Compared with adults, youth with HIV (YHIV) have poorer retention in care, antiretroviral therapy (ART) adherence, and HIV virological suppression (VS) [1] .
Multiple barriers to medication adherence have been identified, including environmental barriers, such as unstable housing, poor health literacy, and underemployment, and barriers related to cognitive development, stigma, and comorbid mental health issues and/or substance use [2, 3] . In adults with HIV, lower pill burden has been shown to be associated better adherence and VS [4] . Simplification to a once-daily single-tablet regimen (STR) first became available in 2006 with the introduction of efavirenz/emtricitabine/tenofovir disoproxil fumarate [5] . Studies have shown that use of STRs is associated with better adherence to ART and VS, when compared with multi-tablet regimens (MTRs) [6] . Additionally, STRs have been shown to improve quality of life in adult patients and improve cost-effectiveness compared with MTRs [7] [8] [9] . The Department of Health and Human Services (DHHS) HIV treatment guidelines for adults and adolescents highlight the importance of using STRs when appropriate to minimize pill burden and aid in adherence [10] . This recommendation is based on data from studies in adults. STRs have been shown to improve adherence outcomes in other groups at high risk for nonadherence, such as homeless and marginally housed adults [11] . However, there are no specific data available on the use of STRs in YHIV, where factors affecting adherence may be complex and adherence has been shown to be lower than for adults [12, 13] .
Given the unique challenges that YHIV face, it is presumed that the increasing use of STRs may increase adherence and VS through decreased pill burden. However, this has not been previously examined specifically in YHIV. The aim of this study was to evaluate the uptake of STRs in YHIV and virological outcomes for YHIV initiating ART with STRs versus MTRs.
Methods
This was a retrospective cohort study examining uptake of STRs and comparing STR and MTR ART initiation in YHIV. Eligible patients were recruited from HIV clinics participating in the HIV Research Network (HIVRN), a consortium of 18 US clinic sites that provide primary and subspecialty care to children, youth, and adults distributed across the USA [14] . As described previously, HIVRN sites abstract specified data elements from patients' medical records, including demographic data, service utilization, medications, and laboratory tests; abstracted data are assembled into a single database after quality assurance review [14] . The Johns Hopkins University School of Medicine Institutional review board (IRB) and the IRBs of each participating institution approved the collection and use of these data for analysis. Data from 13 sites were analysed, four of which were paediatric sites. Patients were included in the analysis if they were between the ages of 13 and 24 years with nonperinatally acquired HIV (nPHIV) and initiated ART between 2006 and 2014, with documented viral load > 400 HIV-1 RNA copies/mL at the time of ART initiation. Patients were included if they had no documented history of ART use. Patients with perinatally acquired HIV were excluded.
Statistical analysis
Three separate outcomes were measured: (1) factors associated with the initiation of STRs versus MTRs, (2) VS at 12 months after ART initiation, and (3) time to VS. STRs were defined as efavirenz/emtricitabine/tenofovir disoproxil fumarate, emtricitabine/rilpivirine/tenofovir disoproxil fumarate, elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate, or abacavir/ dolutegravir/lamivudine. VS was defined as HIV viral load < 400 copies/mL at 12 months, using the viral load measurement closest to 12 months within 9-15 months after initiation. To ensure that the viral load outcome was being associated with the regimen type that was first initiated, patients were excluded if they changed treatment (STR to MTR or MTR to STR) within 9 months after first ART initiation; 9 months was chosen because it was the minimum time-point for assessment of viral load. For viral load outcome analysis, patients who initiated ART in 2014 were excluded as they lacked 12-month follow-up data. Additionally, VS was measured as time to first VS within the first 12 months of ART initiation.
Demographic and clinical characteristics of ART-na€ ıve patients initiating ART with either STRs or MTRs were assessed using the v 2 test for categorical variables and the Wilcoxon rank sum test for continuous variables. Univariate and multivariable logistic regression was used to assess the factors associated with initiation of STRs versus MTRs and factors associated with VS at 12 months after ART initiation. Cox proportional hazard models were used to compare the STR and MTR groups in terms of time to initial VS (< 400 copies/mL) over the 12 months after initiation of ART. The final multivariable and Cox proportional hazards models included gender, race/ethnicity, HIV risk factor, clinical site (paediatric versus adult), CD4 count at ART initiation, viral load at ART initiation, year of ART initiation, and ART exposure history. The proportional hazards assumption was assessed graphically. Analyses were performed with STATA software version 14 (StataCorp, College Station, TX).
Results
A total of 987 YHIV were initiated on ART between 2006 and 2014 and were included in this analysis. The majority were male (84%), were African American (62% (3) 30 (3) 2008 36 (5) 29 (9) 65 (7) 2009 36 (5) 29 (9) 65 (7) 2010 79 (12) 33 (10) 112 (11) 2011 96 (15) 67 (21) 163 (17) 2012 122 (18) 64 (19) 186 (19) 2013 148 (22) 45 (14) 193 (20) 2014 108 (16) 33 (10) 141 (14) Bold P-values are statistically significant. Values are n (%), unless otherwise stated. IQR, interquartile range; MSM, men who have sex with men.
In the multivariate logistic regression model, initiation of an STR was associated with VS at 12 months (AOR 1.61; 95% CI 1.01-2.58) ( Table 2) . VS was also associated with white race (AOR 2.41; 95% CI 1. 13-5.13) and Hispanic ethnicity (AOR 2.38; 95% CI 1.32-4.27) (compared with black race), and CD4 counts of 351-500 cells/lL (AOR 2.90; 95% CI 1.49-5.65) and 500 cells/lL (AOR 3.36; 95% CI 1.56-7.22) compared with < 200 cells/lL. Care at a paediatric center had a trend towards an association with VS (AOR 2.32; 95% CI 0.97-5.55). There was no difference in likelihood of VS among the different STRs.
Of those who initiated ART from 2006 to 2013, 747 had at least one follow-up viral load measurement after ART initiation. Within the first 12 months, those initiated and maintained on an STR achieved the first measurement of VS at a faster rate compared with those initiated on an MTR in the unadjusted model [hazard ratio (HR) 1.22; 95% CI 1.03-1.44]. After adjusting for covariates, the median time to VS was shorter (77 days; 95% confidence interval 68-85 days) in the STR group compared with the MTR group (91 days; 95% confidence interval 77-103 days); however, this difference was not statistically significant (HR 1.07; 95% CI 0.90-1.28).
Discussion
In this multisite cohort, YHIV initiating STRs were more likely to achieve VS 12 months after initiation than YHIV who initiated MTRs. These results are similar to results seen in previous studies focused on adult populations [6, 15] . In addition, STR initiation was associated with male gender, higher CD4 count, and initiation of ART in 2013 and 2014.
The association of STR initiation and male gender probably occurred because of heightened concern about teratogenicity of the efavirenz component of the most commonly prescribed STR during the study period. This association is unlikely to be seen with the other STR agents.
There may be the perception that those with a CD4 count < 200 cells/lL may require a more complex ART regimen thanwas available as an STR, such as regimens containing protease inhibitors, and this may explain the increased likelihood of STR use in those with a higher baseline CD4 count. Higher likelihood of STR use in patients with higher CD4 counts has been shown in other cohort studies focused on adult patients [15] .
Patients were more likely to initiate STRs if ART was initiated in 2013 or 2014, which reflects an increase in available STR options with Food and Drug Administration (FDA) approval of emtricitabine/rilpivirine/tenofovir disoproxil fumarate in 2011, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in 2012 and abacavir/dolutegravir/lamivudine in 2014.
YHIV were seen at either adult or paediatric sites. Care at a paediatric centre, while not associated with initiation of STRs, had a trend towards an association with VS. This finding is consistent with other data published from the HIVRN showing higher rates of treatment discontinuation and loss to follow-up at adult versus paediatric care sites [16, 17] . It is likely that there are factors (youth friendly services, etc.) associated with paediatric care sites that support adherence to ART and maintenance of VS.
A strength of our study is that we evaluated YHIV being followed at HIV clinical sites under non-trial-based conditions with a clinic diversity. However, while HIVRN demographics closely resemble those of people living with HIV in the USA, our sample is not nationally representative. Additionally, factors such as mental health or substance abuse comorbidities are not measured by HIVRN, so were not examined. Our analysis of VS was limited to those with a 12-month measurement of viral load. It is unknown whether the patients who did not have follow-up viral load testing achieved VS as we do not have data on whether those patients engaged in care at other sites or disengaged from care. Additionally, regimen type changes after 9 months were not recorded. Lastly, 72% of the STRs used during the study period consisted of efavirenz/emtricitabine/tenofovir disoproxil fumarate, which with the development of newer regimens with fewer side effects, such as teratogenicity, probably does not reflect current STR use. Although no difference was noted in terms of regimen type and VS, the small numbers of the other regimens make it difficult to compare. The limited number of patients < 18 years old make the results less generalizable to the younger population.
Overall, this study shows increasing uptake of STRs over time among YHIV and that use of STRs in YHIV was associated with VS. These results support US adult and adolescent guidelines recommending STRs to improve adherence and VS. Use of STRs is one component of the complex comprehensive care that this challenging group requires.
